CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Investment analysts at Oppenheimer Holdings lifted their Q3 2017 earnings estimates for shares of CytomX Therapeutics in a research note issued to investors on Tuesday. Oppenheimer Holdings analyst L. Cann now anticipates that the biotechnology company will earn ($0.25) per share for the quarter, up from their prior forecast of ($0.61). Oppenheimer Holdings also issued estimates for CytomX Therapeutics’ Q4 2017 earnings at ($0.67) EPS, FY2017 earnings at ($1.83) EPS, FY2018 earnings at ($0.49) EPS, FY2019 earnings at ($1.79) EPS, FY2020 earnings at ($0.57) EPS and FY2021 earnings at ($1.67) EPS.
CTMX has been the subject of several other reports. Jefferies Group LLC reissued a “buy” rating and set a $25.00 target price on shares of CytomX Therapeutics in a research report on Tuesday, June 6th. Cann reissued a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday. Zacks Investment Research raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research report on Wednesday, May 3rd. BidaskClub downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Finally, Cowen and Company reissued a “buy” rating on shares of CytomX Therapeutics in a research report on Wednesday, June 28th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $25.60.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2797267/q3-2017-eps-estimates-for-cytomx-therapeutics-inc-ctmx-lifted-by-analyst.html.
CytomX Therapeutics (CTMX) opened at 14.40 on Thursday. The stock’s 50 day moving average is $14.72 and its 200-day moving average is $14.49. The firm’s market capitalization is $529.19 million. CytomX Therapeutics has a 1-year low of $9.84 and a 1-year high of $20.02.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.30. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. The business had revenue of $8.75 million for the quarter, compared to analyst estimates of $4.95 million.
Several hedge funds have recently made changes to their positions in the stock. EcoR1 Capital LLC acquired a new stake in shares of CytomX Therapeutics during the first quarter worth approximately $13,729,000. Perceptive Advisors LLC raised its stake in CytomX Therapeutics by 65.7% in the first quarter. Perceptive Advisors LLC now owns 1,530,659 shares of the biotechnology company’s stock worth $26,434,000 after buying an additional 606,896 shares during the period. Driehaus Capital Management LLC purchased a new stake in CytomX Therapeutics during the first quarter worth $5,089,000. JPMorgan Chase & Co. raised its stake in CytomX Therapeutics by 551.5% in the first quarter. JPMorgan Chase & Co. now owns 185,778 shares of the biotechnology company’s stock worth $3,208,000 after buying an additional 157,261 shares during the period. Finally, Sphera Funds Management LTD. purchased a new stake in CytomX Therapeutics during the first quarter worth $2,591,000. Institutional investors own 52.33% of the company’s stock.
In other CytomX Therapeutics news, CFO Debanjan Ray sold 2,500 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $15.47, for a total value of $38,675.00. Following the transaction, the chief financial officer now directly owns 22,126 shares in the company, valued at $342,289.22. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Frederick W. Gluck sold 5,000 shares of the business’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $14.61, for a total transaction of $73,050.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,062 shares of company stock worth $497,641. 4.70% of the stock is owned by corporate insiders.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.